Literature DB >> 27007601

Recent Advances in Application of Pharmacogenomics for Biotherapeutics.

Pramod B Mahajan1.   

Abstract

Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effects, and biocompatible metabolism, in addition to legal and logistic advantages. However, their clinical utility is limited, among other things, by their high immunogenic potential and/or variable therapeutic efficacy in different patient populations. Both of these issues, also commonly experienced with small molecule drugs, have been addressed effectively in a number of cases by the successful application of pharmacogenomic tools and approaches. In this introductory article of the special issue, we review the current state of application of pharmacogenomics to BTs and offer suggestions for further expansion of the field.

Entities:  

Keywords:  biologicals; biotherapeutics; genetic variability; pharmacogenomics

Mesh:

Substances:

Year:  2016        PMID: 27007601      PMCID: PMC5256619          DOI: 10.1208/s12248-016-9903-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  77 in total

Review 1.  Protein therapeutics: new applications for pharmacogenetics.

Authors:  Cecile Krejsa; Mark Rogge; Wolfgang Sadee
Journal:  Nat Rev Drug Discov       Date:  2006-06       Impact factor: 84.694

2.  (Re)defining biopharmaceutical.

Authors:  Ronald A Rader
Journal:  Nat Biotechnol       Date:  2008-07       Impact factor: 54.908

Review 3.  Key considerations in the preclinical development of biosimilars.

Authors:  Lynne A Bui; Susan Hurst; Gregory L Finch; Beverly Ingram; Ira A Jacobs; Carol F Kirchhoff; Chee-Keng Ng; Anne M Ryan
Journal:  Drug Discov Today       Date:  2015-04-23       Impact factor: 7.851

4.  Pharmacogenetics and the Immunogenicity of Protein Therapeutics.

Authors:  Gouri S Pandey; Zuben E Sauna
Journal:  J Interferon Cytokine Res       Date:  2014-12       Impact factor: 2.607

5.  Fresh from the biotech pipeline--2013.

Authors:  Jim Kling
Journal:  Nat Biotechnol       Date:  2014-02       Impact factor: 54.908

Review 6.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

7.  Biopharmaceutical benchmarks 2014.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

Review 8.  Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence.

Authors:  Klaus Bendtzen
Journal:  Front Immunol       Date:  2015-04-08       Impact factor: 7.561

Review 9.  Biosimilar drugs: Current status.

Authors:  Rajiv Kumar; Jagjit Singh
Journal:  Int J Appl Basic Med Res       Date:  2014-07

Review 10.  Biosimilars advancements: Moving on to the future.

Authors:  Lilian Rumi Tsuruta; Mariana Lopes dos Santos; Ana Maria Moro
Journal:  Biotechnol Prog       Date:  2015-03-16
View more
  1 in total

Review 1.  Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.

Authors:  Peter D Kwong; Gwo-Yu Chuang; Brandon J DeKosky; Tatyana Gindin; Ivelin S Georgiev; Thomas Lemmin; Chaim A Schramm; Zizhang Sheng; Cinque Soto; An-Suei Yang; John R Mascola; Lawrence Shapiro
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.